Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility NEW YORK--(BUSINESS WIRE)

Subsidiary Calyxt, Acquires Land for New Headquarters Facility

NEW YORK--(BUSINESS WIRE)--March 1, 2016--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),

a biopharmaceutical company focused on developing immunotherapies based

on gene edited CAR T-cells (UCART), announced today that its wholly

owned subsidiary, Calyxt, Inc., has closed on the purchase of a 10-acre

parcel in the St. Paul suburb of Roseville to build its new headquarters

The new facility, which should be operational around mid-2017, will be

comprised of a 35,000 square-foot office and lab building, with

greenhouses and outdoor research plots.

Calyxt, Inc., is a Minnesota-based company focused on developing

healthier food products to benefit both consumers and growers.

To find out more about Calyxt, please visit their website: www.calyxt.com

Cellectis is a biopharmaceutical company focused on developing

immunotherapies based on gene edited CAR-T cells (UCART). The company's

mission is to develop a new generation of cancer therapies based on

engineered T-cells. Cellectis capitalizes on its 16 years of expertise

in genome engineering - based on its flagship TALEN products and

meganucleases and pioneering electroporation PulseAgile technology - to

create a new generation of immunotherapies. CAR technologies are

designed to target surface antigens expressed on cells. Using its

life-science-focused, pioneering genome-engineering technologies,

Cellectis' goal is to create innovative products in multiple fields and

with various target markets. Cellectis S.A. is listed on the Nasdaq

Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker:

ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it.

TALEN is a registered

trademark owned by the Cellectis Group.

This press release and the information contained herein do not

constitute an offer to sell or subscribe, or a solicitation of an offer

to buy or subscribe, for shares in Cellectis in any country. This press

release contains forward-looking statements that relate to the Company's

objectives based on the current expectations and assumptions of the

Company's management only and involve risk and uncertainties that could

cause the Company to fail to achieve the objectives expressed by the

forward-looking statements above.

Jennifer Moore, 917-580-1088

KCSA Strategic Communications

Harnest, 646-385-9008

VP Finance and Investor Relations